75 related articles for article (PubMed ID: 24576622)
21. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Sato S; Itamochi H; Kigawa J; Oishi T; Shimada M; Sato S; Naniwa J; Uegaki K; Nonaka M; Terakawa N
Cancer Sci; 2009 Mar; 100(3):546-51. PubMed ID: 19154404
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract][Full Text] [Related]
23. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
24. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2011 Nov; 31(11):3789-97. PubMed ID: 22110201
[TBL] [Abstract][Full Text] [Related]
25. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4843-50. PubMed ID: 23155250
[TBL] [Abstract][Full Text] [Related]
26. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations of cells resistant to platinum drugs: role of PKCalpha.
Righetti SC; Perego P; Carenini N; Corna E; Dal Bo L; Cedrola S; La Porta CA; Zunino F
Biochim Biophys Acta; 2006 Jan; 1763(1):93-100. PubMed ID: 16473140
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
29. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.
Benedetti V; Perego P; Luca Beretta G; Corna E; Tinelli S; Righetti SC; Leone R; Apostoli P; Lanzi C; Zunino F
Mol Cancer Ther; 2008 Mar; 7(3):679-87. PubMed ID: 18347153
[TBL] [Abstract][Full Text] [Related]
30. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
31. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
32. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
33. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
34. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
35. The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome.
Ohta T; Isobe M; Takahashi T; Saitoh-Sekiguchi M; Motoyama T; Kurachi H
Anticancer Res; 2009 Nov; 29(11):4639-47. PubMed ID: 20032415
[TBL] [Abstract][Full Text] [Related]
36. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
37. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
38. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
39. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.
Pinato DJ; Graham J; Gabra H; Sharma R
Cancer Treat Rev; 2013 Apr; 39(2):153-60. PubMed ID: 22595680
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]